How does GRFP N's PE Ratio compare to its peers?

GRFP N is expensive based on its Price-To-Earnings Ratio (35.8x) compared to the peer average (22x).

How does GRFP N's PE Ratio compare vs other companies in the Global Biotechs Industry?

GRFP N is expensive based on its Price-To-Earnings Ratio (35.8x) compared to the Global Biotechs industry average (26.6x).

What is GRFP N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate GRFP N's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of GRFP N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

GRFP N (MX$126.63) is trading below our estimate of [[fair value]] (MX$204.25)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Grifols (BMV:GRFP N) - Stock Price, News & Analysis

GRFP N Stock Overview

Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. More details

GRFP N fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 38% below our estimate of its fair value

Earnings are forecast to grow 28.25% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

Interest payments are not well covered by earnings

Grifols, S.A. Competitors

Beijing Tiantan Biological Products

SHSE:600161

CN¥42.9b

Genomma Lab Internacional. de

BMV:LAB B

Mex$25.2b

Alkermes

NasdaqGS:ALKS

US$4.6b

Shanghai RAAS Blood Products

SZSE:002252

CN¥49.1b

Price History & Performance

Summary of all time highs, changes and price drops for Grifols
Historical stock prices
Current Share Price	€126.63
52 Week High	€165.16
52 Week Low	€120.10
Beta	0.70
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-54.94%
5 Year Change	-70.87%
Change since IPO	-48.04%

Recent updates

Shareholder Returns

	GRFP N	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how GRFP N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how GRFP N performed against the MX Market.

Price Volatility

Is GRFP N's price volatile compared to industry and market?
GRFP N volatility
GRFP N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: GRFP N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GRFP N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1909	23,505	Nacho Abia Buenache	www.grifols.com

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.

Grifols, S.A. Fundamentals Summary

How do Grifols's earnings and revenue compare to its market cap?
GRFP N fundamental statistics
Market cap	Mex$112.51b
Earnings (TTM)	Mex$3.46b
Revenue (TTM)	Mex$142.06b

35.8x

P/E Ratio

0.9x

P/S Ratio

Is GRFP N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRFP N income statement (TTM)
Revenue	€6.81b
Cost of Revenue	€4.17b
Gross Profit	€2.64b
Other Expenses	€2.47b
Earnings	€165.67m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)	0.24
Gross Margin	38.76%
Net Profit Margin	2.43%
Debt/Equity Ratio	125.0%

How did GRFP N perform over the long term?

See historical performance and comparison

GRFP N Stock Overview

Rewards

Risk Analysis

Grifols, S.A. Competitors

SHSE:600161

CN¥42.9b

BMV:LAB B

Mex$25.2b

NasdaqGS:ALKS

US$4.6b

SZSE:002252

CN¥49.1b

Price History & Performance

Recent News & Updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021